Xencor Inc (XNCR)

Currency in USD
7.95
-0.03(-0.38%)
Closed·
After Hours
7.950.00(0.00%)
·
XNCR Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected today
Fair Value
Day's Range
7.688.16
52 wk Range
7.1627.24
Key Statistics
Prev. Close
7.95
Open
8.01
Day's Range
7.68-8.16
52 wk Range
7.16-27.24
Volume
595.24K
Average Volume (3m)
842.75K
1-Year Change
-58.55%
Book Value / Share
9.08
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
XNCR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
28.20
Upside
+254.72%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Xencor Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Xencor Inc Company Profile

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases, and cancer. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; and Sotrovimab that targets the SARS-CoV-2 virus. It develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; Vudalimab, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer; XmAb564, to treat autoimmune diseases; XmAb662, which is in Phase I clinical trial to treat patients with solid tumors; XmAb942, which is in Phase I clinical trial for patients with Crohn’s disease and ulcerative colitis; and Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat lymphoma. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; Obexelimab, to treat patients with immunoglobulin G4-related disease; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Tobevibart, a treatment for hepatitis Delta virus infection; Novartis, an antibody drug candidate that uses XmAb Fc technologies; Xpro1595 to treat patients with Alzheimer’s disease and treatment-resistant depression; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat prostate cancer; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.

Xencor Inc SWOT Analysis


Pipeline Promise
Xencor's diverse oncology and immunology pipeline approaches crucial data readouts, with potential to reshape the company's future and market position
Financial Crossroads
Despite strong liquidity, Xencor faces challenges with negative earnings and cash burn, balancing innovation costs against the path to profitability
Expanding Horizons
Delve into Xencor's strategic move into autoimmune diseases, potentially opening new revenue streams and diversifying its therapeutic portfolio
Market Valuation
With analyst targets ranging from $22 to $38, explore the factors influencing Xencor's market perception and potential for value creation
Read full SWOT analysis

Xencor Inc Earnings Call Summary for Q4/2023

  • Vudalimab shows promising results in prostate cancer treatment, with confirmed partial response and PSA90 for over 22 weeks
  • Xencor reducing investment in cytokine drugs, focusing on T-cell engagers for solid tumors; plans to select next IND candidate later this year
  • Company strengthening balance sheet through monetization of Ultomiris and Monjuvi royalties
  • Safety profile of vudalimab well-managed, with few treatment discontinuations; comparable to other checkpoint inhibitors
  • Xencor aims to enroll ~30 patients per cohort for go/no-go decision on vudalimab efficacy; early data encouraging but awaiting further confirmation
Last Updated: 28/02/2024, 17:14
Read Full Transcript

Compare XNCR to Peers and Sector

Metrics to compare
XNCR
Peers
Sector
Relationship
P/E Ratio
−2.7x1.8x−0.5x
PEG Ratio
0.100.000.00
Price/Book
0.9x2.7x2.6x
Price / LTM Sales
4.4x7.3x3.3x
Upside (Analyst Target)
283.6%298.4%43.5%
Fair Value Upside
Unlock22.7%6.3%Unlock

Analyst Ratings

11 Buy
0 Hold
1 Sell
Ratings:
12 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 28.20
(+254.72% Upside)

Earnings

Latest Release
May 07, 2025
EPS / Forecast
-0.66 / -0.62
Revenue / Forecast
32.73M / 18.42M
EPS Revisions
Last 90 days

XNCR Income Statement

People Also Watch

134.94
KRYS
-14.04%
17.10
SRPT
+7.48%
19.88
URGN
+2.47%
5.71
REPL
-24.87%
12.60
CDNA
+3.11%

FAQ

What Stock Exchange Does Xencor Inc Trade On?

Xencor Inc is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Xencor Inc?

The stock symbol for Xencor Inc is "XNCR."

What Is the Xencor Inc Market Cap?

As of today, Xencor Inc market cap is 565.81M.

What Is Xencor Inc's Earnings Per Share (TTM)?

The Xencor Inc EPS (TTM) is -3.05.

When Is the Next Xencor Inc Earnings Date?

Xencor Inc will release its next earnings report on 04 Aug 2025.

From a Technical Analysis Perspective, Is XNCR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Xencor Inc Stock Split?

Xencor Inc has split 0 times.

How Many Employees Does Xencor Inc Have?

Xencor Inc has 250 employees.

What is the current trading status of Xencor Inc (XNCR)?

As of 05 Aug 2025, Xencor Inc (XNCR) is trading at a price of 7.95, with a previous close of 7.95. The stock has fluctuated within a day range of 7.68 to 8.16, while its 52-week range spans from 7.16 to 27.24.

What Is Xencor Inc (XNCR) Price Target According to Analysts?

The average 12-month price target for Xencor Inc is USD28.2, with a high estimate of USD40 and a low estimate of USD6. 11 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Strong Buy. The stock has an +254.72% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.